|
MXPA02003436A
(es)
|
1999-10-07 |
2002-08-20 |
Amgen Inc |
Inhibidores de triazina cinasa.
|
|
EP1175205B1
(en)
|
1999-11-12 |
2006-06-14 |
Abbott Laboratories |
Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
|
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
|
KR20030024659A
(ko)
|
2000-02-17 |
2003-03-26 |
암겐 인코포레이티드 |
키나제 억제제
|
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
|
CA2439468A1
(en)
|
2001-02-27 |
2002-09-06 |
Teva Pharmaceutical Industries Ltd. |
New crystal forms of lamotrigine and processes for their preparations
|
|
MXPA03011784A
(es)
|
2001-06-22 |
2004-04-02 |
Pfizer Prod Inc |
Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
|
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
|
JO3429B1
(ar)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
JP4460292B2
(ja)
|
2001-10-17 |
2010-05-12 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
|
|
SE0104140D0
(sv)
*
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
ATE511858T1
(de)
|
2002-02-05 |
2011-06-15 |
Astellas Pharma Inc |
2,4,6-triamino-1,3,5-triazin-derivat
|
|
WO2003090693A2
(en)
*
|
2002-04-23 |
2003-11-06 |
Teva Pharmaceutical Industries Ltd. |
Pharmaceutical composition containing lamotrigine particles of defined morphology
|
|
AR039540A1
(es)
*
|
2002-05-13 |
2005-02-23 |
Tibotec Pharm Ltd |
Compuestos microbicidas con contenido de pirimidina o triazina
|
|
AU2003249369A1
(en)
|
2002-06-21 |
2004-01-06 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
|
IL166241A0
(en)
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
US7399856B2
(en)
|
2002-08-09 |
2008-07-15 |
Janssen Pharmaceutica N.V. |
Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
|
|
SI1551372T1
(en)
*
|
2002-09-20 |
2018-08-31 |
Alpharma Pharmaceuticals Llc |
SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
|
|
WO2004048343A1
(en)
*
|
2002-11-28 |
2004-06-10 |
Schering Aktiengesellschaft |
Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
|
|
AU2002350719A1
(en)
*
|
2002-11-29 |
2004-06-23 |
Janssen Pharmaceutica N.V. |
Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
|
|
RS20050532A
(sr)
|
2003-01-14 |
2007-12-31 |
Arena Pharmaceuticals Inc., |
Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
|
|
EP1597237B1
(en)
*
|
2003-02-07 |
2016-07-27 |
Janssen Pharmaceutica NV |
Pyrimidine derivatives for the prevention of HIV infection
|
|
CL2004000303A1
(es)
*
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
EP1648467B1
(en)
|
2003-07-17 |
2018-03-21 |
Janssen Sciences Ireland UC |
Process for preparing particles containing an antiviral
|
|
ES2421139T3
(es)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
ES2328820T3
(es)
|
2003-10-17 |
2009-11-18 |
Astrazeneca Ab |
Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
|
|
PT1725540E
(pt)
|
2004-03-05 |
2012-11-29 |
Hoffmann La Roche |
Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
|
|
US7951805B2
(en)
|
2004-09-20 |
2011-05-31 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
|
|
EP1804799B1
(en)
|
2004-09-20 |
2013-08-21 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
EP1799667B1
(en)
|
2004-09-20 |
2013-03-20 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
|
US7767677B2
(en)
|
2004-09-20 |
2010-08-03 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
CA2580856A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
EP2289510A1
(en)
|
2004-09-20 |
2011-03-02 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
|
EP2316458A1
(en)
|
2004-09-20 |
2011-05-04 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
|
|
ATE540035T1
(de)
|
2004-11-24 |
2012-01-15 |
Rigel Pharmaceuticals Inc |
Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
US7449458B2
(en)
|
2005-01-19 |
2008-11-11 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
KR101362621B1
(ko)
|
2005-02-16 |
2014-02-13 |
아스트라제네카 아베 |
화합물
|
|
US7935711B2
(en)
*
|
2005-02-18 |
2011-05-03 |
Tibotec Pharmaceuticals Ltd. |
HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
|
|
DK1858861T3
(da)
*
|
2005-03-04 |
2010-11-08 |
Tibotec Pharm Ltd |
HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner
|
|
AR056652A1
(es)
|
2005-04-11 |
2007-10-17 |
Tibotec Pharm Ltd |
Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
|
|
CA2608009A1
(en)
|
2005-05-16 |
2006-11-23 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
|
CN101248051B
(zh)
|
2005-05-26 |
2013-07-17 |
泰博特克药品有限公司 |
制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
|
|
EP2029138A1
(en)
|
2005-06-03 |
2009-03-04 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
AU2006286576B2
(en)
|
2005-09-01 |
2012-06-14 |
F. Hoffmann-La Roche Ag |
Diaminopyrimidines as P2X3 and P3X2/3 modulators
|
|
ES2562056T3
(es)
|
2005-09-01 |
2016-03-02 |
F. Hoffmann-La Roche Ag |
Diaminopirimidinas como moduladores P2X3 y P2X2/3
|
|
ES2612890T3
(es)
|
2005-09-01 |
2017-05-19 |
F. Hoffmann-La Roche Ag |
Diaminopirimidinas como moduladores de P2X3 y P2X2/3
|
|
BRPI0618011A2
(pt)
|
2005-10-28 |
2011-08-16 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
|
|
WO2007056205A2
(en)
*
|
2005-11-04 |
2007-05-18 |
Eastman Chemical Company |
Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
|
|
ATE522202T1
(de)
*
|
2006-06-06 |
2011-09-15 |
Tibotec Pharm Ltd |
Verfahren zur herstellung von sprühgetrockneten formulierungen von tmc125
|
|
SI2484346T1
(sl)
|
2006-06-19 |
2017-05-31 |
Alpharma Pharmaceuticals Llc |
Farmacevtski sestavki
|
|
CA2665726C
(en)
*
|
2006-10-11 |
2016-04-19 |
Alpharma, Inc. |
Pharmaceutical compositions
|
|
WO2008068299A2
(en)
*
|
2006-12-06 |
2008-06-12 |
Tibotec Pharmaceuticals Ltd. |
Hydrobromide salt of an anti-hiv compound
|
|
AR065720A1
(es)
*
|
2007-03-14 |
2009-06-24 |
Tibotec Pharm Ltd |
Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
AU2008262031B2
(en)
*
|
2007-06-08 |
2011-08-25 |
Boehringer Ingelheim International Gmbh |
Extended release formulation of nevirapine
|
|
JP2010531301A
(ja)
*
|
2007-06-25 |
2010-09-24 |
テイボテク・フアーマシユーチカルズ |
ダルナビル及びエトラビリンを含んでなる組み合わせ調剤
|
|
EP2212298B1
(en)
*
|
2007-10-18 |
2013-03-27 |
Concert Pharmaceuticals Inc. |
Deuterated etravirine
|
|
US7989465B2
(en)
*
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
JP5600063B2
(ja)
|
2007-10-19 |
2014-10-01 |
セルジーン アビロミクス リサーチ， インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
US20090196890A1
(en)
*
|
2007-12-17 |
2009-08-06 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical compositions
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
WO2010022128A1
(en)
*
|
2008-08-20 |
2010-02-25 |
Schering Corporation |
Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
|
CA2734487A1
(en)
*
|
2008-08-20 |
2010-02-25 |
Southern Research Institute |
Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
|
JP2012502906A
(ja)
*
|
2008-09-17 |
2012-02-02 |
ネクター セラピューティックス |
オリゴマー−プロテアーゼ阻害剤コンジュゲート
|
|
CN101744823B
(zh)
*
|
2008-12-17 |
2013-06-19 |
广东东阳光药业有限公司 |
一种二氢嘧啶类化合物的固体分散体及其药用制剂
|
|
WO2010112411A1
(en)
|
2009-03-30 |
2010-10-07 |
Tibotec Pharmaceuticals |
Co-crystal of etravirine and nicotinamide
|
|
CA2764818A1
(en)
*
|
2009-06-08 |
2010-12-16 |
California Capital Equity, Llc |
Triazine derivatives and their therapeutical applications
|
|
ES2527103T3
(es)
*
|
2009-06-22 |
2015-01-20 |
Emcure Pharmaceuticals Limited |
Procedimiento para la síntesis de etravirina
|
|
AU2011260323A1
(en)
|
2010-06-04 |
2012-11-15 |
F. Hoffmann-La Roche Ag |
Aminopyrimidine derivatives as LRRK2 modulators
|
|
CN103221410B
(zh)
|
2010-09-22 |
2017-09-15 |
艾尼纳制药公司 |
Gpr119受体调节剂和对与其相关的障碍的治疗
|
|
KR101566091B1
(ko)
|
2010-11-10 |
2015-11-04 |
에프. 호프만-라 로슈 아게 |
Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
JP6185559B2
(ja)
*
|
2012-04-11 |
2017-08-23 |
ダウ グローバル テクノロジーズ エルエルシー |
有機希釈剤およびセルロースエーテルを含む組成物
|
|
WO2013154977A1
(en)
*
|
2012-04-11 |
2013-10-17 |
Dow Global Technologies Llc |
Novel sustained release dosage forms
|
|
EP2836517B1
(en)
*
|
2012-04-11 |
2016-07-27 |
Dow Global Technologies LLC |
Melt-extruded composition comprising a cellulose ether
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
EP2872492B1
(en)
*
|
2012-07-12 |
2018-01-31 |
Hetero Research Foundation |
Process for the preparation of rilpivirine using a novel intermediate
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CA3002540C
(en)
|
2015-01-06 |
2023-11-07 |
Arena Pharmaceuticals, Inc. |
Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
CA2976790C
(en)
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AR100459A1
(es)
*
|
2015-05-15 |
2016-10-05 |
Química Luar S R L |
Una composición farmacéutica antiviral de uso tópico
|
|
JP6838744B2
(ja)
|
2015-06-22 |
2021-03-03 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
|
|
CN110520124A
(zh)
|
2017-02-16 |
2019-11-29 |
艾尼纳制药公司 |
用于治疗原发性胆汁性胆管炎的化合物和方法
|
|
WO2018187652A1
(en)
|
2017-04-06 |
2018-10-11 |
Janssen Pharmaceutica Nv |
2,4-diaminopyrimidine derivatives as histamine h4 modulators
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
JP7397011B2
(ja)
|
2018-06-06 |
2023-12-12 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｓ１ｐ１受容体に関連する状態を治療する方法
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021104487A1
(en)
|
2019-11-29 |
2021-06-03 |
Aptorum Therapeutics Limited |
Composition including rilpivirine and use thereof for treating tumors or cancer
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
KR102145925B1
(ko)
|
2020-03-03 |
2020-08-19 |
협동조합 바이오융합기술 |
사포닌 성분이 함유된 항 바이러스용 조성물의 제조방법
|
|
CN111875548A
(zh)
*
|
2020-07-16 |
2020-11-03 |
山东大学 |
一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN116425683A
(zh)
*
|
2023-04-04 |
2023-07-14 |
上药康丽（常州）药业有限公司 |
一种米诺地尔的合成精制方法
|